Jolie Bou-Gharios

Jolie Bou-Gharios

Auto-generated profile, based on publicly available information

Jolie Bou-Gharios

Institut de Cancérologie Strasbourg Europe, 67000 Strasbourg, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2024 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JBJolie Bou-Gharios
Jolie Bou-Gharios
GNGeorges Noel
Georges Noel
HBHélène BURCKEL
Hélène BURCKEL
Glioblastoma multiforme (GBM) is the most common adult primary brain tumor. The standard clinical treatment of GBM includes a maximal surgical resection followed by concomitant radiotherapy (RT) and chemotherapy sessions with Temozolomide (TMZ) in addition to adjuvant TMZ cycles. Despite the severity of this protocol, GBM is highly resistant and recurs in almost all cases while the protocol remains unchanged since 2005. Limited-diffusion or chronic hypoxia has been identified as one of the major key players driving this aggressive phenotype. The presence of hypoxia within the tumor bulk contributes to the activation of hypoxia signaling pathway mediated by the hypoxia-inducing factors (HIFs), which in turn activate biological mechanisms to ensure the adaptation and survival of GBM under limited oxygen and nutrient supply. Activated downstream pathways are involved in maintaining stem cell-like phenotype, inducing mesenchymal shift, invasion, and migration, altering the cellular and oxygen metabolism, and increasing angiogenesis, autophagy, and immunosuppression. Therefore, in this review will discuss the recent preclinical and clinical approaches that aim at targeting tumor hypoxia to enhance the response of GBM to conventional therapies along with their results and limitations upon clinical translation.

2 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ICIsabelle Chambrelant
Isabelle Chambrelant
DJDelphine Jarnet
Delphine Jarnet
JBJolie Bou-Gharios
Jolie Bou-Gharios
CFClara Le Fèvre
Clara Le Fèvre
LKLaure Kuntz
Laure Kuntz
GNGeorges Noel
Georges Noel
Stereotactic radiotherapy (SRT) plays a major role in treating brain metastases (BMs) and can be delivered using various equipment and techniques. This review aims to identify the dosimetric factors of each technique to determine whether one should be preferred over another for single BMs treatment. A systematic literature review on articles published between January 2015 and January 2022 was conducted using the MEDLINE and ScienceDirect databases, following the PRISMA methodology, using the keywords “dosimetric comparison” and “brain metastases”. The included articles compared two or more SRT techniques for treating single BM and considered at least two parameters among: conformity (CI), homogeneity (HI) and gradient (GI) indexes, delivery treatment time, and dose-volume of normal brain tissue. Eleven studies were analyzed. The heterogeneous lesions along with the different definitions of dosimetric indexes rendered the studied comparison almost unattainable. Gamma Knife (GK) and volumetric modulated arc therapy (VMAT) provide better CI and GI and ensure the sparing of healthy tissue. To conclude, it is crucial to optimize dosimetric indexes to minimize radiation exposure to healthy tissue, particularly in cases of reirradiation. Consequently, there is a need for future well-designed studies to establish guidelines for selecting the appropriate SRT technique based on the treated BMs’ characteristics.

4 February 2025 in Nanoscale
Verified
Journal Article
Open access
PDF file
MRMaría de Los Angeles Ramírez
María de Los Angeles Ramírez
JBJolie Bou-Gharios
Jolie Bou-Gharios
BFBarbara Freis
Barbara Freis
JDJulien Draussin
Julien Draussin
CCClémence Cheignon
Clémence Cheignon
SHSébastien Harlepp
Sébastien Harlepp
Developing and synthesizing nano-objects capable of enabling early targeted diagnosis and ensuring effective tumor treatment represents a significant challenge in the theranostic field. Among various nanoparticles (NPs), iron oxide nanoparticles (IONPs) have made significant contributions to advancing this field. However, a key challenge lies in achieving selective recognition of specific cell types. In oncology, the primary goal is to develop innovative strategies to enhance NP uptake by tumors, primarily through active targeting. This involves adding targeting ligands (TL) to the NP surface to facilitate tumor accumulation and increase retention within the tumor microenvironment. Despite biofunctionalization strategies, overall tumor uptake remains modest at only 5–7% of the injected dose per gram. In this work, we demonstrate the effect of spacing between the NPs and the TL to improve their availability and thus the tumor uptake of the complex. This proof-of-concept study targets the epidermal growth factor receptor (EGFR) using a peptide as a targeting ligand. Specifically, we characterized the PEG-peptide coupled to dendronized IONPs, including the density of grafted TL. These nano-objects underwent in vitro evaluation to assess their ability to specifically target and be internalized by tumor cells. Therapeutically, compared to non-functionalized NPs, the presence of the TL with a PEG linker enhanced targeting efficacy and increased internalization, leading to improved photothermal efficacy.

25 September 2024 in Cancer/Radiothérapie
Verified
Journal Article
Open access
GNGeorges Noel
Georges Noel
JBJolie Bou-Gharios
Jolie Bou-Gharios
HBHélène BURCKEL
Hélène BURCKEL
The radiobiology of tumor reirradiation is poorly understood. It pertains to tumors and their sensitivity at the time of relapse, encompassing primary tumors, metastases, or secondary cancers developed in or proximal to previously irradiated tissues. The ability to control the pathology depends, in part, on understanding this sensitivity. To date, literature data remains limited regarding changes in the radiosensitivity of tissues after initial irradiation, and most proposals are based on conjecture. The response of healthy tissues at the site of irradiation raises concerns about radio-induced complications. Cumulative dose is likely a major factor in this risk, thus using equivalent dose calculations might help reduce the risk of complications. However, the correlation between mathematical equivalence formulas and clinical effects of radiobiological origin is weak, and the lack of knowledge of the alpha/beta (α/β) ratio of healthy tissues remains an obstacle to the extensive use of these formulas. However, tissues exposed to recovery dose may have a tolerance to irradiation much higher than assumed, thus further biological work remains to be developed. Also, the functionality of previously irradiated tissues could be useful in selecting the most suitable irradiation beams. Finally, research on the genomics of irradiated healthy tissues could improve the prediction of side effects and personalize radiotherapy.

18 October 2022 in Radiation
Verified
Journal Article
Open access
PDF file
LBLarry Bodgi
Larry Bodgi
JCJoelle AL CHOBOQ
Joelle AL CHOBOQ
TATarek Araji
Tarek Araji
JBJolie Bou-Gharios
Jolie Bou-Gharios
JAJoyce Azzi
Joyce Azzi
Wassim Abou-KheirWassim Abou-Kheir
Wassim Abou-Kheir
While radical cystectomy remains the primary treatment of choice for bladder cancer, increased evidence supports the use of bladder-preservation strategies based on adjuvant radiotherapy. This highlights the need for a better understanding of bladder cancer radiosensitivity to different types of treatment deliveries. The purpose of this study is to analyze the effect of treatment time, dose and fractionation on the number and sizes of grown three-dimensional (3D) bladder cancer spheres, and to assess the capacity of the linear-quadratic model in describing the response of cells cultured in 3D. 3D MatrigelTM-based cultures were employed to enrich for cancer stem cells (CSCs) from three human bladder cancer cell lines, RT4, T24 and UM-UC-3. Three single dose radiation treatments were performed at different time points after plating, and sphere number and sizes were assessed. Anti-CD44 immunofluorescence, clonogenic assay and anti-γH2AX staining were also performed to analyze the cell lines’ radiosensitivity. The radiosensitivity of spheres was dependent on the treatment timing after plating. Current linear quadratic dose fractionation models were shown to over-estimate radiosensitivity in 3D models. Our results showed the importance of treatment timing on the radio-response of bladder cancer spheres. We also demonstrated that bladder cancer spheres are more resistant to dose-fractionation than the estimation from the theoretical linear-quadratic model.

19 February 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
Hisham BahmadHisham Bahmad
Hisham Bahmad
RCReda M. Chalhoub
Reda M. Chalhoub
HHhayat Omar Harati
hayat Omar Harati
JBJolie Bou-Gharios
Jolie Bou-Gharios
FBFarah Ballout
Farah Ballout
Wassim Abou-KheirWassim Abou-Kheir
Wassim Abou-Kheir
Neuroblastoma is an embryonic tumor that represents the most common extracranial solid tumor in children. Resistance to therapy is attributed, in part, to the persistence of a subpopulation of slowly dividing cancer stem cells (CSCs) within those tumors. Glycogen synthase kinase (GSK)-3β is an active proline-directed serine/threonine kinase, well-known to be involved in different signaling pathways entangled in the pathophysiology of neuroblastoma. This study aims to assess the potency of an irreversible GSK-3β inhibitor drug, Tideglusib (TDG), in suppressing proliferation, viability, and migration of human neuroblastoma cell lines, as well as its effects on their CSCs subpopulation in vitro and in vivo . Our results showed that treatment with TDG significantly reduced cell proliferation, viability, and migration of SK-N-SH and SH-SY5Y cells. TDG also significantly inhibited neurospheres formation capability in both cell lines, eradicating the self-renewal ability of highly resistant CSCs. Importantly, TDG potently inhibited neuroblastoma tumor growth and progression in vivo . In conclusion, TDG proved to be an effective in vitro and in vivo treatment for neuroblastoma cell lines and may hence serve as a potential adjuvant therapeutic agent for this aggressive nervous system tumor.